These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3815730)

  • 21. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the activity of PALA by dipyridamole.
    Chan TC; Young B; King ME; Taetle R; Howell SB
    Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG; Davis TE; Falkson G; Keller AM
    Am J Clin Oncol; 1982 Dec; 5(6):627-9. PubMed ID: 7165004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Casper ES; Young CW
    Cancer Res; 1983 May; 43(5):2317-21. PubMed ID: 6187448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
    Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
    J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA; Ardalan B; Multhauf P; Chan C; Staples R; Green L; Browning S; Carr BI; Chang FF; Thayer W
    Med Pediatr Oncol; 1983; 11(3):162-3. PubMed ID: 6222250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
    Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH; Harstrick A; Hiddemann W; Schöffski P; Wilke H; Bokemeyer C; Dörken B; Schmoll HJ
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
    Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
    Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ
    Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
    Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.
    Bedikian AY; Stroehlein JR; Karlin DA; Bennetts RW; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1981; 65(9-10):747-53. PubMed ID: 7273010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.